Washington, D.C. 20549








BioNTech SE

(Translation of registrant’s name into English)


An der Goldgrube 12 D-55131 Mainz Germany

+49 6131-9084-0

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F Form 40‑F

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7):







Description of Exhibit




Presentation: Corporate Presentation January 2020.



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



BioNTech SE









/s/ Dr. Sierk Poetting



Name: Dr. Sierk Poetting



Title: Chief Financial Officer





Date: January 27, 2020



Slide 1

Corporate Presentation January 2020 Exhibit 99.1

Slide 2

This slide presentation includes forward-looking statements Forward-Looking Statements Various statements in this slide presentation concerning the future expectations of BioNTech, its plans and prospects, including the Company’s views with respect to the potential for mRNA therapeutics, its expectations with respect to the timing and results of clinical trials and release of clinical data (both in respect of its proprietary product candidates and of product candidates of its collaborators), the development of commercial capabilities and the transition of BioNTech to a fully integrated biopharmaceutical company, its expectations with respect to interactions with regulatory authorities such as FDA and EMA, including the potential approval of BioNTech’s or its collaborators’ current or future drug candidates, and expected royalty and milestone payments in connection with BioNTech’s collaborations, constitute forward-looking statements. Words such as "expects," "plans," "potential," "target," "continue" and variations of these words or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on the current beliefs and assumptions of the management team of BioNTech and on the information currently available to the management team of BioNTech, and are subject to change. The Company will not necessarily inform you of such changes. These forward looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause the Company’s actual results, performance or achievements to be materially different than any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the initiation, timing, progress, results and cost of the Company's research and development programs and its current and future preclinical studies and clinical trials; the timing of and the Company's ability to obtain and maintain regulatory approval for its product candidates; the Company's ability to identify research opportunities and discover and develop investigational medicines; the Company's expectations regarding the size of the patient populations for its product candidates, if approved for commercial use; the Company's estimates of its expenses, ongoing losses, future revenue and capital requirements and its needs for or ability to obtain additional financing; the Company's ability to identify, recruit and retain key personnel; the Company's and its collaborators' ability to protect and enforce its intellectual property protection for its proprietary and collaborative product candidates, and the scope of such protection; the development of and projections relating to the Company's competitors or its industry; the Company's ability to commercialize its product candidates, if approved; the rate and degree of market acceptance of the Company's investigational medicines; the Company's ability to manage its development and expansion; regulatory developments in the United States and foreign countries; the Company's ability to manufacture its product candidates with advantages in turnaround times or manufacturing cost; and the Company's ability to implement, maintain and improve effective internal controls. The preceding list is not intended to be an exhaustive list of all of the Company's forward-looking statements. Any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. The mRNA vaccines and other product candidates discussed in this slide presentation are investigational products being developed by BioNTech and its collaborators and are not currently approved by the FDA, EMA or any other regulatory authority.

Slide 3

Agenda Who we are and what we do Our key platforms and programs Outlook in 2020 and beyond +

Slide 4

Building a 21st century individualized immunotherapy company Executive summary Large addressable market opportunity in solid tumors More than USD 90bn solid tumor market3 addressed Commercialization or co-commercialization rights retained in key geographies World-leading collaborators 7 pharmaceutical collaborators and multiple leading academic institutions 50:50 cost and profit share agreements with leaders in oncology1 Broad & diversified pipeline 10 product candidates in the clinic First registrational trial expected to start in 20202 Next generation immunotherapies for cancer and other diseases Technology agnostic approach Exploiting novel targets and mechanisms Vertical Integration with in house manufacturing Up to 7 clinical data updates expected in the next 18 months 1with Genentech and Genmab; 2BNT111; 3Source: Global Data Total WW Market, top 10 available products 2018-2024 + other

Slide 5

Our Vision: We aspire to individualize cancer medicine Overview mRNA Therapeutics Engineered Cell Therapies Antibodies Small Molecule Immunomodulators Off-the-shelf drugs Interindividual variability Tailored-on-demand immunotherapies Clinical samples Sample profiling bioinformatics big data, deep data AI platforms Drug classes In-house diagnostics & bio-informatics Multi-drug platform approach Off-the-shelf drugs and individualized therapies In-house manufacturing with on-demand production capabilities A patient centric approach

Slide 6

Achievements 2019 and Outlook 2020 2019 accomplishments: Raised USD 225m in Series B financing and USD 149m in Nasdaq IPO Initiated 6 clinical trials across 2 drug classes and 4 different platforms Started first randomized phase 2 trial for iNeST Dosed more than 440 patients across all BNTX programs1 as of end 2019 Entered into strategically important agreements with Bill & Melinda Gates Foundation and Regeneron Site for building new iNeST manufacturing facility purchased, planning and design work initiated, secured loan of USD 55m (EUR 50m) from European Investment Bank (EIB) Goals for 2020: Start 8 or more clinical trials (alone or with our collaborators) Move FixVac into a pivotal phase 3 trial and iNeST into additional phase 1/2 clinical trials Further invest in individualized manufacturing capacities Establish presence on East Coast of US 1 BNTX programs: all BioNTech trials including trials sponsored by collaborators Year in review and outlook

Slide 7

A technology agnostic approach increases our addressable market Solid tumor market segmentation Cancer segment Patient Population Challenge Our Therapeutic Strategy High mutational burden/ adjuvant stage cancers Significant portion of cancer patients Poor risk-benefit profile of checkpoint inhibitors mRNA Neoantigen Immunotherapy (iNeST) Low mutational burden cancers >60% of cancers Poor response to checkpoint inhibitors Shared Antigens (FixVac, CAR-T cells, Antibodies) “Immune desert” cancers >40% of high-mutational cancers Poor infiltration and activation of T-cells in TME1 mRNA Immunotherapy Immunostimulatory Compounds (intratumoral, RiboCytokines) Cancers with MHC / B2M loss 20-30% of CPI-experienced advanced cancers Failure of immune system to recognize tumor cells Antibodies CAR-Ts Refractory tumors Patients with large tumors and multiple resistance mechanisms Few treatment options Engineered Cell Therapies Combination Therapies Portfolio approach based on molecular classification and segmentation of cancer types 1Tumor microenvironment

Slide 8

…and enables us to exploit our proprietary cancer antigen library Our approach Tumor Associated Antigens (TAAs) Cancer-selective antigens Over the past 15 years, we have built up a database of ~200 of tumor associated antigens, including proprietary targets Viral Neoantigens Mutant Neoantigens Virus-derived proteins Safe and promising targets for immunotherapy: Absent from any non-infected tissue Highly immunogenic Not subject to immune escape Antigens derived from sequence-altered (mutated) proteins Promising targets for cancer immunotherapy: Drive highly specific activation of the immune system (recognized as foreign) Exempt from central tolerance Description and rationale Antigen type and platform Cancer-Germline and Cancer-Embryo-Fetal Antigens FixVac Antibodies CAR-T Tissue Restricted Differentiation Antigens FixVac Antibodies Tumor-Associated Carbohydrate Antigens Antibodies CAR-T Viral Oncoantigen Targets E6 & E7 for FixVac program in HPV16+ H&N cancer FixVac Mutant Neoantigens for individualized Neoantigen Specific Immunotherapy (iNeST) iNeST

Slide 9

We have pioneered a truly individualized immunotherapy approach… Our approach Sequencing Sequence patient’s tumor and healthy tissue using next-generation sequencing technology Compare patient’s sequenced tumor and healthy samples to identify targets for the design of individualized cancer immunotherapies Mutation Detection (MyMUT1) Technology combines tumor modeling with mutation detection MyMUT is a next-generation mutation detection system combining High specificity Robustness at low tumor content Intratumor heterogeneity Quality control Suitable for routine clinical specimen Neoepitope Selection Only a portion of mutated peptides (neoepitopes) are suitable for raising an immune response in vivo. Our approach focuses on evoking responses involving both CD8+ T cells and CD4+ T cells Continuously evolving Machine Learning and Artificial Intelligence algorithms, data collection from various sources Note: 1Exclusively licensed from TRON

Slide 10

…and ability to leverage deep OMICS capabilities across all our platforms Our approach: deep OMICS capabilities HT NGS HiSeq NovaSeq 6000 10X Genomics Chromium HT qRT-PCR Fluidigm Biomark NGS analysis pipelines seq2HLA MyMut® uMut® Target validation (CD8+, CD4+, antibodies) Pre-clinical models & mode of action Immunology & immune therapies Immune monitoring Flow cytometry and sorting ELISpot Animal models and imaging Syngeneic and xenogeneic models In vivo imaging Target expression RNA vectors Cloning Histology Immunohistochemistry Cryo-immunofluorescence Molecular Cancer Profiling Immune Response Analyses Next-generation sequencing (NGS) Genomics Bioinformatics, Machine Learning, Artificial Intelligence High-Performance Computing Collaboration with TRON Translational Research Center

Slide 11

Collaborating with leaders in oncology 50:50 Cost and Profit share (2016) 50:50 Cost and Profit share (2015) Cost and Profit share (2015) Co-development and Co-commercialization of novel mRNA-based, individualized cancer vaccines (iNeST – BNT122) USD 310m upfront & near-term payments 50/50 cost and profit share on global profits Genentech conducting ongoing clinical trials BioNTech with right to co-commercialize in the US and certain European markets Co-Development and co-commercialization of Bispecific antibodies (BNT311, BNT312) USD 10m upfront milestones 50/50 cost and profit share on global profits Genmab conducting ongoing clinical trials BioNTech with right to co-commercialize worldwide Development and commercialization of up to 5 intratumoral mRNA cancer immunotherapies, e.g., BNT131 USD 60m upfront and milestones; extended collaboration in 2018 with equity investment Potential for up to EUR 260m in development, regulatory, and commercial milestones on each of the immunotherapies (with up to low double-digit royalties on net sales) Option to convert the financial terms for 2 of these immunotherapies to a cost and profit share arrangement (first option exercised) BioNTech with right to co-commercialize in the US and certain EU markets Our strategy to commercialize our own products is reflected by differentiated collaboration agreements

Slide 12

Collaborating with leaders in oncology, infectious diseases and rare diseases Our other collaboration agreements are structured to expand our footprint while managing risk Co-development Co-commercialization (2018) Co-development and Co-commercialization agreement for 5 mRNA protein replacement therapies for rare diseases 50/50 global cost and profit share For each co-development project, one or the other party will take lead responsibility for commercialization (and book sales) 5 exclusive oncology LNP licenses to BioNTech – Genevant to receive milestones and royalties on oncology licenses mRNA based prophylactic flu vaccine (BNT161) USD 120m in upfront, equity investment and first milestones Up to USD 325m in potential additional milestone payments Up to very low double-digit royalties on worldwide sales mRNA based vaccines in up to 10 infectious disease collaborations R&D payments to Penn of USD 15m, with USD 5m paid on signing UPenn to conduct preclinical testing of mRNA vaccine compounds BioNTech retains the option to license in the mRNA vaccine candidates for clinical development; milestones and royalties to be paid under certain circumstances HIV and tuberculosis (TB) and up to 3 additional infectious diseases USD 55m as an equity investment to advance prevention and/or treatment of HIV and TB Up to USD 45m in additional grants to fund additional activities in up to 3 additional infectious disease projects within the first 5 years of the collaboration Novel tumor targets and corresponding T-cell receptors USD 60m in upfront and equity investment Potential development, regulatory, and commercial milestones up to an aggregate of approx. USD 300m Up to very low double-digit royalties per drug candidate Licensing Agreement (2018) Strategic R&D Alliance (2018) R&D Agreement (2019) Licensing Agreement (2015) UPenn

Slide 13

We own in-house manufacturing capabilities for individualized treatments mRNA Manufacturing: Unique process utilizing digitization and automation/robotics to ensure robust, consistent repeatability, quality control and on-demand manufacturing 2 mRNA GMP production facilities: Idar-Oberstein (GMP since 2011) and Mainz (GMP since 2018) Completion and GMP licensure of new Mainz facility for iNeST expected in 2022/23 We intend to further strengthen our position as a leader in the highly automated, on-demand production of individualized therapies. Manufacturing footprint Cell & Gene Therapy Manufacturing: Innovative and robust cell therapy manufacturing process Idar-Oberstein: GMP certified cell and gene therapy facility since 1999 Ongoing facility expansion providing additional, state-of-the-art cell therapy manufacturing capacity

Slide 14

We are led by an experienced and entrepreneurial team Management team Supervisory Board Helmut Jeggle Managing Director, Athos Former Head of Business Planning & Analyses at Hexal Michael Motschmann Founder of MIG Verwaltungs AG Significant experience in building companies Prof. Christoph Huber, MD Co-founder of BioNTech Prof. Emeritus at the Mainz University Dr. Ulrich Wandschneider Former CEO at Asklepios Kliniken Scientific Advisory Board Prof. Dr. Rolf Zinkernagel Nobel Prize in Physiology or Medicine in 1996 for his discovery of immune recognition of virus-infected cells Professor Emeritus at Zurich University Prof. Dr. Hans Hengartner Professor Emeritus at ETH Zurich and University of Zurich World renowned immunologist Management Prof. Ugur Sahin, MD Co-Founder and CEO Sean Marett CBO / CCO Dr. Özlem Türeci Co-Founder and CMO Dr. Sierk Poetting CFO / COO Ryan Richardson Chief Strategy Officer

Slide 15

Building a global biotechnology company Company footprint BNT office planned San Diego Mainz Berlin Munich  Idar-Oberstein USA Germany

Slide 16

Agenda Who we are and what we do Our key platforms and programs Outlook in 2020 and beyond +

Slide 17

We have a broad pipeline of mRNA product candidates in oncology Our pipeline Drug Class Platform Product Candidate Indication (Targets) Preclinical Phase 1 Phase 2 Rights Collaborator Milestones Oncology mRNA FixVac (fixed combination of shared cancer antigens) BNT111 advanced melanoma (adjuvant & metastatic) fully-owned report phase 1 data and phase 2 start 1H 2020; phase 3 start 2H 2020 BNT112 prostate cancer fully-owned BNT113 HPV16+ head and neck cancer1 fully-owned phase 2 start 2H 2020 BNT114 triple negative breast cancer fully-owned data update 1H 2020 BNT115 ovarian cancer1 fully-owned BNT116 NSCLC fully-owned iNeST (patient specific cancer antigen therapy) RO7198457 (BNT1224) 1L melanoma with CPI2 Genentech (global 50:50 profit/loss top line data 2H 20203 multiple solid tumors data update 2020 Intratumoral Immunotherapy SAR441000 (BNT131) solid tumors (IL-12sc, IL-15sushi, GM-CSF, IFNα) Sanofi (global profit/ loss share) data update 2H 20205 1BNT113 and BNT115 are currently being studied in investigator-initiated phase 1 trials; 2Checkpoint Inhibitor; 3Update on the ongoing study including patient enrollment number, efficacy and safety data for an interim update expected in the second half of 2021; 4BNT122 (iNeST) is also being investigated in arm 2 (N=15) of the 3 arm TNBC-MERIT trial, with BNT114 as an optional treatment; BNT114 is investigated in arm 1 (N=12) and arm 3 (N=15) of the TNBC-MERIT trial (total patients in study: N=42; 5As the trial is sponsored and conducted by Sanofi, the timing of data updates is not under our control and is subject to change by Sanofi

Slide 18

We have a broad pipeline of mRNA product candidates in oncology... Our pipeline Drug Class Platform Product Candidate Indication (Targets) Preclinical Phase 1 Phase 2 Rights Collaborator Milestones Oncology mRNA RiboMabs (mRNA-encoded antibodies) BNT141 multiple solid tumors fully-owned phase 1 start 2H 2020 BNT142 multiple solid tumors (CD3+CLDN6) fully-owned phase 1 start 2H 2020 or 1H 2021 RiboCytokines (mRNA-encoded Cytokines) BNT151 multiple solid tumors (optimized IL-2) fully-owned phase 1 start 1H 2020 BNT152+ BNT153 multiple solid tumors (IL-7, IL-2) fully-owned phase 1 start 2H 2020 or 1H 2021

Slide 19

We expect additional oncology trial starts in 2020 - with first data in 2021 Our pipeline Drug Class Platform Product Candidate Indication (Targets) Preclinical Phase 1 Phase 2 Rights Collaborator Milestones Oncology Engineered Cell Therapies CAR-T Cells BNT211 multiple solid tumors (CLDN6) fully-owned phase 1/2 start 1H 2020 BNT212 pancreatic, other cancers (CLDN18.2) fully-owned - TCRs Undisclosed undisclosed Eli Lilly (exclusive license) - To be selected all tumors fully-owned - Antibodies Next-Gen CP5 Immunomodulators GEN1046 (BNT311) multiple solid tumors (PD-L1×4-1BB) Genmab (global 50:50 profit/loss) data update 2H 2020 GEN1042 (BNT312) multiple solid tumors (CD40×4-1BB) - Targeted Cancer Antibodies BNT321 (MVT-5873) pancreatic cancer (sLea) fully-owned SMIM6 Toll-Like Receptor Binding BNT411 solid tumors (TLR7) fully-owned phase 1 start 1H 2020 5Checkpoint; 6Small Molecule Immunomodulators

Slide 20

Our first trial starts outside of oncology are expected by the end of 2020 Our pipeline 1We are eligible to receive worldwide licenses; 2Protein Replacement Therapy Drug Class Platform Product Candidate Indication (Targets) Preclinical Phase 1 Phase 2 Rights Collaborator Milestones Other mRNA Infectious Disease Immunotherapies Undisclosed Influenza Pfizer start first study by end of 2020 Undisclosed up to 10 indications Penn1 first phase 1 trial to start 1H 2021 Undisclosed HIV and tuberculosis Bill & Melinda Gates Foundation - Rare Disease PRT2 BNT171 Not disclosed Genmab (global 50:50 profit/loss) first phase 1 trial to start 2H 2020 Undisclosed 5 rare disease indications -

Slide 21

Targeting Cancer Immunomodulation mRNA Cancer Vaccines Antibody Targeting Small Molecule Immunomodulators Next Generation Immunomodulators FixVac, iNeST Targeted Antibodies RiboMabs Engineered Cell Therapies CAR-T, TCRs Bispecific Antibodies (CPI + co-stimulation) TLR agonist Engineered Cytokines Intratumoral cytokines RiboCytokines Our IO strategy exploits complementary therapeutic platforms Our multi-platform approach + We expect to have all core platforms in the clinic by the end of 2020 1 2020 In the clinic 1 1 1 2020

Slide 22

Agenda Who we are and what we do Our key platforms and programs mRNA vaccines – FixVac and iNeST Antibodies CARVac platform – CLDN6 CAR-T RiboCytokines Outlook in 2020 and beyond Small Molecule Immunomodulator program

Slide 23

One of the broadest mRNA toolkits in the industry Local Intratumoral Systemic Tissue specific Adjustable activity in vivo from minutes up to weeks Various delivery routes Liposomes / LPX LNPs Polyplexes Broad formulation spectrum Multiple mRNA formats uRNA modRNA saRNA taRNA 5’ Cap 5’ UTR ORF 3’ UTR Poly(A) tail mRNA drug class | formulations and formats

Slide 24

We have developed multiple proprietary mRNA formats and formulations Our mRNA formats Lipoplex: Our lipoplex formulation, or LPX, embeds the mRNA between a lipid bilayer, which is used for our FixVac and iNeST platforms LNPs: For other applications, we encapsulate our mRNA in lipid nanoparticles, or LNPs. These formulations are suitable for our RiboMab, RiboCytokine and rare disease protein replacement therapy platforms Polyplexes: Our portfolio also comprises polyplexes, which are being utilized in certain of our discovery programs, in which the mRNA is bound to a polymer and then forms nanoparticles Our mRNA delivery formulations Lipoplexes (FixVac, iNeST, CARVac) LNPs (RiboMabs, RiboCytokines, Rare Disease) Polyplexes (Discovery Programs) OUR mRNA FORMATS Uridine mRNA (uRNA) Repeat administration Strong T cell responses Nucleoside-modified mRNA (modRNA) Non-immunogenic vector Strong antibody responses Therapeutic protein delivery Self-amplifying mRNA (saRNA) Sustained expression T cell responses upon prime only Protection upon prime only Trans-amplifying mRNA (taRNA): Replicase and mRNA Sustained expression Highly flexible co-transfer Low antigen RNA doses mRNA drug class | formulations and formats

Slide 25

We are developing multiple mRNA therapeutic platforms mRNA Platform Drug Targets mRNA Formats Delivery Formulations 7 mRNA platforms Broad range of biological targets 4 types of mRNA Multiple optimized formulations Oncology FixVac Shared Antigens uRNA RNA-LPX iNeST Neoepitopes uRNA RNA-LPX Intratumoral Immunotherapy Immunomodulators modRNA Various formulations Intratumoral RiboMabs mAb targets modRNA LNPs Intravenous delivery RiboCytokines Cytokines modRNA Various LNP formulations Other Infectious Disease Vaccines Pathogens saRNA, taRNA, modRNA Various LNPs for i.m. & s.c. delivery Rare Disease Protein Replacement Therapy Diverse Proteins modRNA Liver targeted LNPs uRNA: uridine mRNA; modRNA: nucleoside-modified mRNA; saRNA: self-amplifying mRNA; taRNA: trans-amplifying mRNA; mRNA drug class | targets, formulations and formats

Slide 26

Our mRNA vaccine platforms: FixVac and iNeST mRNA drug class | vaccine platforms Off-the-shelf mRNA immunotherapy Targeting a fixed combination of shared antigens Non-mutated antigens shared among patients with a specific cancer type Applicable for almost all types of tumor antigens FixVac iNeST FixVac Fully individualized mRNA immunotherapy Targeting 20 neo-antigens unique to each patient Vast majority of neo-antigens are unique to individual patients Applicable across solid tumor types Proprietary RNA-LPX formulation for systemic dendritic cell targeting Strong immunogenicity observed in vivo via TLR7-driven adjuvant effect Potent induction of strong ex vivo CD4+ and CD8+ T cell responses Kranz et al., Nature 2016

Slide 27

. 2.1% 10.1% 10.3% Strong vaccine-induced ex vivo CD8+ T cell responses1 across different cancer types FixVac iNeST HPV16-E7 Head Neck Cancer BNT113, HARE40 trial Mutant Neoantigen TNBC BNT114, TNBC MERIT trial MAGE-A3 Melanoma BNT111, Lipo-MERIT trial NY-ESO-1 Melanoma BNT111, Lipo-MERIT trial 5.0% 1T cell responses analyzed by ex vivo multimer staining analysis in blood mRNA drug class | vaccine platforms Our RNA-LPX vaccine approach

Slide 28

Cumulative patient coverage of FixVac Melanoma targets is over 90% Computational pipeline for antigen-discovery and RT-PCR validation RNA-Seq data from 337 melanoma samples in TCGA Target-criteria High expression in melanoma No expression in toxicity-relevant normal cells and tissues Coverage of as many patients as possible with at least 1 antigen Coverage of a substantial fraction of patients with more than 1 antigen Tyrosinase MAGEA3 NY-ESO-1 TPTE mRNA drug class | FixVac platform | BNT111 (FixVac Advanced Melanoma)

Slide 29

FixVac: BNT111 Interim clinical activity data (dose range 14µg -100µg) Summary Advanced melanoma patients (stage III, IV) Out of 74 patients with available follow-u radiological imaging 42 patients were assessed for preliminary analysis as of July 29, 2019 of 25 patients with metastatic melanoma who received BNT111 monotherapy following progression on CPI* and in some cases other therapies 3 patients with partial response (PR) 1 patient with metabolic complete response 7 patents with stable disease (SD) 14 progressive disease (PD) of 17 patients with metastatic melanoma who received BNT111 in combination with CPI after progression on CPI monotherapy 6 patients with partial response (PR) 2 patents with stable disease (SD) 9 progressive disease (PD) Adjuvant cohort of 32 patients still in study mRNA drug class | FixVac platform | BNT111 (FixVac advanced melanoma) *CPI: Checkpoint inhibitor Shared Antigens Targeted NY-ESO-1 / MAGE-A3 / Tyrosinase / TPTE

Slide 30

BNT112: FixVac Prostate Cancer mRNA drug class | FixVac platform | BNT112 (FixVac Prostate Cancer) Ph1/2: first patient enrolled in December 2019 Multipronged vaccine: Targeted antigens of BNT112 are 5 prostate cancer specific antigens (PAP, PSA and 3 undisclosed antigens) RNA-LPX vaccine format validated by our FixVac Melanoma program Antigen 1 PSA PAP Antigen 4 Antigen 5 Antigen 1 PSA PAP Antigen 4 Antigen 5

Slide 31

FixVac: a flexible format which can rapidly be adapted for different tumors Initiation of additional clinical studies in other solid tumor indications Metastatic melanoma HPV16+ positive head & neck cancer (IIT) Triple negative breast cancer Prostate cancer BNT111 BNT113 BNT114 BNT112 BNT115 Preclinical Phase 1 Phase 2 Product candidate Ph 2 start H1 2020 Ph 3 start H2 2020 Ph 2 start 2H 2020 Data update 1H 2020 mRNA drug class | FixVac platform NSCLC BNT116 Ovarian cancer (IIT) 5 programs in human trials

Slide 32

Individualized Neoantigen Specific Immunotherapy (iNeST) mRNA drug class | iNeST platform | clinical trials Overview Targeting multiple neoantigens Intended to be a universal approach applicable for the majority of cancers 50:50 profit/loss share with Genentech Turnaround time reduced from three months to six weeks BNT121 (i.n.) BNT122 (IV) Preclinical Phase 1 Phase 2 Up to 41 mon follow-up data Data update 2020 Top line data 2H 2020 New planned trial expected to start in 2020 Multiple solid tumors Metastatic melanoma (N=13) First-line advanced melanoma in combination with pembrolizumab (Keytruda) First-line adjuvant solid cancer in combination with atezolizumab (Tecentriq) First-line adjuvant solid cancer Currently being evaluated in ≥ 8 solid tumor indications

Slide 33

Conclusions from iNeST clinical trials mRNA drug class | iNeST platform | clinical trials Clinical efficacy evaluation in randomized phase 2 trials initiated Long-term follow-up of completed trial with BNT121 (Intra-nodal administration, RNA): Long-term relapse free disease activity with BNT121 iNeST in adjuvant melanoma Preliminary observations in ongoing trials with BNT122 (RO7198457) (IV administration, RNA-LPX): iNeST can be manufactured for individual patients with clinically relevant turn-around times across a range of tumor types iNeST +/- atezolizumab (Tecentriq) has a manageable safety profile Strong iNeST immunogenicity across a range of tumor types

Slide 34

Update for BNT121 (as of October 2019) mRNA drug class | iNeST platform | BNT121 Metastatic relapse analyses 9 of 13 patients without documented PFS events Melanoma Stage IIIB, IIIC, and IV, 13 patients, intranodal delivery against 10 neoantigens Sahin et al., Nature 2017 Stable progression free survival in adjuvant melanoma

Slide 35

BNT121: Interim clinical activity data (dose range 14µg -100µg) New Metastases Relapse free disease control 13 High relapse risk melanoma patients (stage IIIB, IIIC, IV) 13 patients 8 5 Stable Disease Complete Response 1 Partial Response 1 Complete Response (Combination with CPI) 1 Progression after temporary disease control (†18 months) 1 Lost to follow-up at 15 months 1 Clinical outcome in follow up Clinical status mRNA drug class | iNeST platform | BNT121 8 Neo-epitope RNA production Neo-epitope RNA vaccination, continued treatment, follow up RNA vaccination Metastatic melanoma (N=13) First-in-human Phase 1 with 13 patients with melanoma stage IIIB, IIIC, and IV; intranodal delivery Immune responses against at least one neoantigen in all patients Cumulative rate of metastatic events significantly reduced, resulting in a sustained PFS 3 out of 5 pts with melanoma relapses developed treatment-related objective clinical responses One complete response (CR), relapse-free 26 mon One immunotherapy-related partial response (PR) One CR in combination with anti-PD1 8 patients (no detectable lesions at start) relapse free and recurrence-free for the whole follow-up (12 to 23 months) Sahin et. al. Nature 2017

Slide 36

iNeST: Results expected for phase 1 in 2020, for phase 2 in 2H 2020 Phase 1a/1b in Multiple Solid Tumors: Open-label, dose-escalation study of safety and pharmacokinetics Phase 2 in Advanced Melanoma: Interventional open-label, multicenter randomized study of efficacy and safety Enrollment: Up to 770 Start date: Dec 2017 Data update: 2020 Tumor types:Melanoma, NSCLC, bladder cancer, CRC, TNBC, renal cancer, H&N cancer, other solid tumors Phase 1a:Single-agent Phase 1b:Combination with atezolizumab Primary outcome measures in iNeST + atezolizumab treated participants compared with iNeST-only participants include: Dose-limiting toxicities (DLTs) Adverse events (AEs) Single-agent escalation Combo escalation (PCV + atezolizumab) Combo exploration/expansion Indication-specific expansions, emphasis on detecting combo signal as quickly as possible Enrollment: 132 Start date: Jan 2019 Topline data: 2H 2020 Tumor types:Advanced melanoma Phase 2:Combination with pembrolizumab Study to evaluate the efficacy and safety of iNeST in combination with pembrolizumab vs. pembrolizumab alone in participants previously untreated in advanced melanoma (first-line) Primary endpoint in iNeST+ pembrolizumab treated participants compared with pembrolizumab-only participants: Progression-free survival (PFS) mRNA drug class | iNeST platform | BNT122

Slide 37

Agenda Who we are and what we do Our key platforms and programs mRNA vaccines – FixVac and iNeST Antibodies CARVac platform – CLDN6 CAR-T RiboCytokines Outlook in 2020 and beyond Small Molecule Immunomodulator program

Slide 38

BNT311 (GEN1046) BNT312 (GEN1042) Next-Gen checkpoint immunomodulators PD-L1 4-1BB K409R F405L Fc-silencing mutations matched CH3 mutations L234F L235E D265A CD-40 4-1BB K409R F405L Fc-silencing mutations matched CH3 mutations L234F L235E D265A Two bispecific antibodies partnered with Genmab Potential “first-in-class” bispecific antibodies Conditional activation of immuno-stimulatory checkpoint activity 50:50 profit/loss share Both programs are now in the clinic Preclinical Phase 1 Phase 2 PD-L1x4-1BB Product Candidate CD-40x4-1BB Ph1/2a Ph1/2a Data update 2H 2020 Antibodies drug class | bispecific antibodies | anti-PDL1, anti-4-1BB

Slide 39

Characteristics Bispecific antibody combining constitutive CPI blockade and conditional co-stimulatory activity Enhanced prolife-ration of antigen specific activated T cells in the presence of PD-L1+ cell Constitutive PD-L1 blockade & conditional 4-1BB agonism 1 2 Increased tumor infiltrating lymphocyte (TIL) expansion in human tumor tissue cultures ex vivo 3 Induced tumor regression of murine tumors superior to pure PD-L1 blockage and is associated with an increase in tumor-specific CD8 T-cells Mode of Action Antibodies drug class | bispecific antibodies | anti-PDL1, anti-4-1BB Preclinical antitumor activity beyond PDL1 blockade PDL1 Blockade 41BB Agonism *SITC 2018, Altintas et al Next-Gen checkpoint immunomodulators

Slide 40

Bispecific antibody GEN1046 (BNT311): Phase 1/2a in solid tumors First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 (PD-L1x4-1BB) in subjects with malignant solid tumors Enrollment: 192 Data update: 2H 2020 Tumor types:Malignant Solid Tumors Intervention: GEN1046 (BNT311) is a PD-L1x4-1BB bispecific antibody that induces conditional activation of T cells through 4-1BB stimulation which is dependent on simultaneous binding to PD-L1 GEN1046 (BNT311) IV once every 21 days Dose levels determined by the starting dose and the escalation steps taken in the trial Description: Open-label safety trial Two parts, a dose escalation (phase 1, first-in-human) and an expansion part (phase 2a) Key Primary endpoints: Dose limiting toxicity Adverse events Safety laboratory parameters Antibodies drug class | bispecific antibodies | anti-PDL1, anti-4-1BB

Slide 41

BNT321 (MVT-5873) BNT321: Cancer antibody targeting Cancer Associated Carbohydrate sLea sLea Phase 1 resumed in 2H 2019 Antibodies drug class | targeted cancer antibodies Pancreatic ductal adenocarcinoma Colon carcinoma Lung adenocarcinoma Urinary bladder, mucinous adenocarcinoma Colon metastatic to ovary Breast carcinoma, lymph node AACR 2016, Abstract CT026, Ragupathi_Maffuid sLea expression in human cancers 1Engle et al, Science 2019: The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice Characteristics Fully human IgG1 mAb with subnanomolar affinity, potent cell killing by ADCC &CDC activity. Targets sialyl Lewis A epitope (sLea) epitope present in a range of glyco-proteins collectively known as CA19-9 CA19-9 is specifically expressed in pancreatic and various other cancers. Shedded CA19-9 is a prognostic marker in these cancers CA19-9 is functionally associated with carcinogenesis1 Preliminary data Six patients evaluated in combination with chemotherapy; four of them met the criteria for partial response and two patients met the criteria for stable disease. BNT321 was generally well tolerated by all six patients    First patient enrolled to resume the BNT321 trial against pancreatic cancer in December 2019

Slide 42

Agenda Who we are and what we do Our key platforms and programs mRNA vaccines – FixVac and iNeST Antibodies CARVac platform – CLDN6 CAR-T RiboCytokines Outlook in 2020 and beyond Small Molecule Immunomodulator program

Slide 43

Complete eradication of advanced tumors demonstrated in an ovarian carcinoma xenograft model BNT211: Next generation CAR-T targeting CLDN6 with CARVac “primer” Engineered Cell Therapies | CAR-T therapies | BNT211 CAR-T cell therapy + RNA Vaccine to amplify CAR-T cell in vivo CLDN6 is not present in healthy tissues CLDN6 is expressed in multiple cancers Ovarian cancer Testicular tumor Lung cancer

Slide 44

BNT211: Next generation CAR-T targeting CLDN6 with CARVac “primer” Engineered Cell Therapies | CAR-T therapies | BNT211 RNA-lipoplex vaccine enhances expansion & persistence of CAR T Applicability shown for CLDN6, CLD18.2, CD19 CAR-T cells 1Reinhard et al, Science 2020: An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors

Slide 45

Further development of engineered T cell therapies Key Plans Start first-in-human trial for CLDN6 CAR-T in solid tumors Second CAR-T in pipeline for solid tumors: CLDN18.2 CAR-T Develop CARVac with other CAR-T therapies Plan to announce first TCRs for TCR engineered therapies Expansion of certified GMP T cell manufacturing facilities planned to be completed in 2020 Idar-Oberstein: GMP certified Cell Therapy Manufacturing Front view model of final layout with the existing buildings A/B and the new buildings C and D (D behind B). C D B A Engineered Cell Therapies | CAR-T therapies | Manufacturing

Slide 46

Agenda Who we are and what we do Our key platforms and programs mRNA vaccines – FixVac and iNeST Antibodies CARVac platform – CLDN6 CAR-T RiboCytokines Outlook in 2020 and beyond Small Molecule Immunomodulator program

Slide 47

RiboCytokines: a novel therapeutic platform k Preclinical Product Candidate Optimized IL-2 Phase 1 Phase 2 IL-7, IL-2 BNT151 BNT152 Pharmacokinetic Profile RiboCytokine Recombinant cytokine Expected to enter the clinic in 2H 2020 k Preclinical Product Candidate Optimized IL-2 Phase 1 Phase 2 IL-7, IL-2 BNT151 BNT152 / BNT153 combo Expected to enter the clinic in 1H 2020 Expected to enter the clinic in 2H 2020 The Concept Cytokines encoded by mRNA and produced in the patient Improved PK properties to improve tolerability and activity Cytokine design to improve immunological properties and tolerability Therapeutic Goals Overcome resistance mechanisms by therapeutic synergy Improve activity of mRNA Vaccines Worldwide rights; wholly owned mRNA drug class | RiboCytokines

Slide 48

CT26 tumor model, vaccine antigen: gp70 CT26 tumor model, tumor size: 60mm2 CR: complete response, vaccine antigen:gp70 Vaccine + aPD-L1 + Effect of tumor size on treatment success of vaccination + aPD-L1 RiboCytokines boost the clinical activity of vaccination + aPD-L1 in large tumors mRNA drug class | RiboCytokines RiboCytokines boost clinical activity of vaccination and PD-L1 blockade

Slide 49

Agenda Who we are and what we do Our key platforms and programs mRNA vaccines – FixVac and iNeST Antibodies CARVac platform – CLDN6 CAR-T RiboCytokines Outlook in 2020 and beyond Small Molecule Immunomodulator program

Slide 50

BNT411: TLR7 agonist has entered the clinical stage Intravenously administered small molecule TLR7 (toll-like receptor 7) agonist Engineered for high potency and high selectivity for TLR7 receptor at the therapeutically active dose range Activates both adaptive and innate immune system Type 1 interferon-dominated release of cytokines and chemokines and potent stimulation of antigen-specific CD8+ T cells, B cells and innate immune cells such as NK cells and macrophages To be used in combination with chemotherapy and checkpoint inhibitors. Qualifies for various solid tumor indications and small cell lung cancer IND filed in November 2019 We expect to initiate a Phase 1/2a clinical trial as a mono and combination therapy in solid tumors in H1/2020 Small Molecule Immunomodulators | TLR7 agonist | BNT411 Planned study design for FIH trial: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC) H1 2020

Slide 51

Multiple angles for therapeutic synergy across platforms Our multi-platform approach BNT211: First-of-kind CLDN-6 CAR-T approach utilizing CAR-T Amplifying RNA Vaccine (CARVac). Significant amplification of CAR-T cells in preclinical studies (published in SCIENCE, 2020) mRNA Cancer Vaccines Engineered Cell Therapies + Engineered Cytokines mRNA Cancer Vaccines Ribocytokine IL-2 (BNT151): Amplification of vaccine induced T cell response in pre-clinical studies + FixVac Melanoma (BNT111): Induces objective responses in CPI-experienced patients iNeST (BNT122): Currently in Phase 2 in combination with CPI in 1L Melanoma. 2 adjuvant trials planned in 2020 mRNA Cancer Vaccines Approved PD1/PL1 Inhibitors + Broad therapeutic potential across a range of solid tumors

Slide 52

Agenda Who we are and what we do Our key platforms and programs Outlook in 2020 and beyond +

Slide 53

We expect a significant news flow in the upcoming 12-18 months Platform Candidate Indication (Target) 1H-2020 2H-2020 20213 20223 FixVac BNT111 Advanced Melanoma BNT112 Prostate Cancer BNT113 HPV16+ H&N Cancer BNT114 Triple Negative Breast Cancer iNeST RO7198457 (BNT122) 1L Melanoma with CPI Multiple ST (basket trial) Intratumoral Immunotherapy SAR441000 (BNT131) Solid tumors (IL-12sc, IL-15sushi, GM-CSF, IFNα) RiboMabs BNT141 Multiple ST BNT142 Multiple ST (CD3+CLDN6) RiboCytokines BNT151 Multiple ST (Optimized IL-2) BNT152/153 Multiple Solid Tumors (IL-7, IL-2) CAR-T Cells BNT211 Multiple ST (CLDN6) Next-Gen CP Immunomodulators BNT311 Multiple ST (PD-L1x4-1BB) BNT312 Multiple ST (CD40x4-1BB) Antibodies BNT321 Pancreatic Cancer (CA19-9) TLR7 Ligand BNT411 Multiple ST (TLR7) Infectious and Rare Diseases Influenza Up to 10 Infectious Disease Indications 5 Rare Disease Indications mRNA Others Phase 2/3 Phase 1/2 Phase 2 Phase 1 Start Phase 1 Start Phase 1 Start Phase 1 Report Phase 1 Phase 1/2 Report Phase 1/2 1We expect this topline data update to include an update on the ongoing study, including patient enrollment numbers, with full efficacy and safety data for an interim update expected in the second half of 2021; 2As the trial is sponsored and conducted by Sanofi, the timing of data updates is not under our control, and is subject to change by Sanofi. 3Our expectations for timing of milestones beyond 2020 are premised on and subject to the achievement of earlier milestones on their expected timelines. Press releases will be issued once first patient has been dosed. Start Phase 2 Start Phase 3 Start Phase 2 Start Phase 1 Report Phase 1/22 Trial progress update1 Data update Phase 1/2 Start Phase 1/2 Expected news flow Expected begin of trial Expected data readout / update Legend Data update Phase 1 Start first study Start first Phase 1 Start first Phase 1 Start Phase 1 Report Phase 1/2 ST: solid tumors

Slide 54

Building a 21st century immunotherapy company Our goals 2020 Outlook 5 trial updates (incl. publishing BNT111 FixVac Melanoma phase 1/2 data in peer reviewed journal) Initiate phase 3 registrational trial for BNT111 FixVac Melanoma Initiate 2 additional iNeST trials in adjuvant stage cancers Initiate phase 1/2 trial using CARVac (BNT211) in CLDN6+ solid tumors (e.g., ovarian, testicular) Initiate phase 2 trial in HPV16+ H&N cancer Continue to build global clinical development organization (US development team on East Coast) 1 2 3 4 5 6

Slide 55

© Copyright BioNTech SE 2019. All Rights Reserved. Jan 27, 2020 An der Goldgrube 12 55131 Mainz Germany T: +49 6131 9084-0 F: +49 6131 9084-390 M: